0000899243-22-009241.txt : 20220303 0000899243-22-009241.hdr.sgml : 20220303 20220303205402 ACCESSION NUMBER: 0000899243-22-009241 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220301 FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Habibizad Nazila CENTRAL INDEX KEY: 0001913961 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 22711737 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-03-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001913961 Habibizad Nazila C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 27960 D Stock Option (Right to buy) 12.95 2026-02-08 Common Stock 23597 D Stock Option (Right to buy) 29.75 2027-02-28 Common Stock 9000 D Stock Option (Right to buy) 59.60 2028-01-31 Common Stock 8000 D Stock Option (Right to buy) 48.44 2029-01-31 Common Stock 5475 D Restricted Stock Units Common Stock 1875 D Stock Option (Right to buy) 46.99 2029-09-30 Common Stock 8000 D Restricted Stock Units Common Stock 5500 D Stock Option (Right to buy) 65.82 2030-02-02 Common Stock 3724 D Restricted Stock Units Common Stock 2327 D Stock Option (Right to buy) 48.73 2030-03-31 Common Stock 2329 D Restricted Stock Units Common Stock 913 D Restricted Stock Units Common Stock 6300 D Stock Option (Right to buy) 44.48 2031-02-28 Common Stock 23424 D Restricted Stock Units Common Stock 11694 D The shares of Common Stock underlying the stock option vested as to 25% of the original grant for 30,000 shares on January 11, 2017 and in 12 equal quarterly installments thereafter through January 11, 2020. The shares of Common Stock underlying the stock option vested in 16 quarterly installments after February 1, 2017 through February 1, 2021. The shares of Common Stock underlying the stock option vested in 16 quarterly installments after March 1, 2018 through March 1, 2022. The shares of Common Stock underlying the stock option vest in 16 quarterly installments after February 1, 2019 through February 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the original grant of 7,500 Restricted Stock Units ("RSUs") vest in eight semi-annual installments after February 1, 2019 through February 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the stock option vest in 16 quarterly installments after October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the original grant of 11,000 RSUs vest in eight semi-annual installments after October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the stock option vest in 16 quarterly installments after February 1, 2020 through February 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the original grant of 4,655 RSUs vest in eight semi-annual installments after February 1, 2020 through February 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the stock option vest in 16 quarterly installments after April 1, 2020 through April 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the original grant of 1,461 RSUs vest in eight semi-annual installments after April 1, 2020 through April 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the stock option vests in 16 quarterly installments after March 1, 2021 through March 1, 2025, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the original grant of 13,364 RSUs vest in eight semi-annual installments after March 1, 2021 through March 1, 2025, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Executive Vice President, Operations Exhibit 24.1 - Power of Attorney /s/ Miguel Carrillo, Attorney-in-Fact 2022-03-03 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                           LIMITED POWER OF ATTORNEY

      The undersigned hereby constitutes and appoints each of Jeffrey Farrow,
Tricia Suvari, Carrie Krehlik, Adam Chinnock and Miguel Carrillo, signing
singly, and with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:

      (1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Global Blood Therapeutics, Inc. (the
"Company"), from time to time the following U.S. Securities and Exchange
Commission ("SEC") forms: (i) Form ID, including any attached documents, to
effect the assignment of codes to the undersigned to be used in the
transmission of information to the SEC using the EDGAR System; (ii) Form 3,
Initial Statement of Beneficial Ownership of Securities, including any attached
documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of
Securities, including any attached documents; (iv) Form 5, Annual Statement of
Beneficial Ownership of Securities in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended, and the rules thereunder,
including any attached documents; (v) Schedules 13D and 13G and (vi) amendments
of each thereof, in accordance with the Securities Exchange Act of 1934, as
amended, and the rules thereunder, including any attached documents;

      (2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any
such Form 3, 4 or 5, Schedules 13D and 13G or any amendment(s) thereto, and
timely file such form(s) with the SEC and any securities exchange, national
association or similar authority; and

      (3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

      The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorneys-in-fact.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee
of the Company.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of February 18, 2022.

                              /s/ Nazila Habibizad
                              -------------------------------
                              Nazila Habibizad